A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

NCT03883100 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia - Accelerated Phase

Interventions

DRUG: HQP1351

Sponsor

Ascentage Pharma Group Inc.